ArticleGynecologic oncology2025
Racial/ethnic disparities in time from diagnosis to surgical treatment for type I and type II endometrial carcinomas.
Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endometrial cancer therapy in 2026.Current opinion in obstetrics & gynecology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTimeliness of cancer care has been recognized as an indicator of quality of care for numerous cancer sites. Differences in endometrial cancer type may contribute to racial/ethnic disparities in treatment outcomes. This study examines racial/ethnic disparities in time to surgical treatment among type I and type II endometrial cancers.
methodsWe used data from 33,626 women with endometrial cancer in the California Cancer Registry between 2000 and 2019. Descriptive statistics, bivariate analyses, univariate logistic regression models, and multivariate logistic regression models stratified by endometrial cancer type (type I or type II) were performed.
resultsSurgical treatment delays were apparent in 35.3 % (n = 22,487) of type I and 34.6 % (n = 11,139) of type II endometrial cancers; treatment delays varied across racial/ethnic group. Among type I endometrial cancers, multivariable models indicate that American Indian/Alaska Native (odds ratio [OR] 1.47, 95 % CI 1.10-1.97, p < 0.05), Black (OR 1.41, 95 % CI 1.23-1.62, p < 0.001), Hispanic/Latina (OR 1.23, 95 % CI 1.15-1.33, p < 0.001), and Asian or Pacific Islander (OR 1.12, 95 % CI 1.02-1.22, p < 0.01) women had higher odds of experiencing treatment delays compared with White women. Among type II endometrial cancers, multivariable models indicate that Black (OR 1.36, 95 % CI 1.18-1.56, p < 0.001) and Hispanic/Latina (OR 1.15, 95 % CI 1.03-1.28, p < 0.05) women had higher odds of experiencing treatment delays compared with White women.
conclusionsTargeted interventions are needed to address racial/ethnic disparities in time to surgical treatment for endometrial cancer to ensure equitable access to timely and appropriate cancer care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.